A Short Corticosteroid Course Reduces Symptoms and Immunological Alterations Underlying Long-COVID.
corticosteroids
immunological alterations
long-COVID
Journal
Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304
Informations de publication
Date de publication:
26 Oct 2021
26 Oct 2021
Historique:
received:
30
09
2021
revised:
21
10
2021
accepted:
23
10
2021
entrez:
27
11
2021
pubmed:
28
11
2021
medline:
28
11
2021
Statut:
epublish
Résumé
Despite the growing number of patients with persistent symptoms after acute SARS-CoV-2 infection, the pathophysiology underlying long-COVID is not yet well characterized, and there is no established therapy. We performed a deep immune profiling in nine patients with persistent symptoms (PSP), before and after a 4-day prednisone course, and five post-COVID-19 patients without persistent symptoms (NSP). PSP showed a perturbed distribution of circulating mononuclear cell populations. Symptoms in PSP were accompanied by a pro-inflammatory phenotype characterized by increased conventional dendritic cells and augmented expression of antigen presentation, co-stimulation, migration, and activation markers in monocytes. The adaptive immunity compartment in PSP showed a Th1-predominance, decreased naïve and regulatory T cells, and augmentation of the PD-1 exhaustion marker. These immune alterations reverted after the corticosteroid treatment and were maintained during the 4-month follow-up, and their normalization correlated with clinical amelioration. The current work highlights an immunopathogenic basis together with a possible role for steroids in the treatment for long-COVID.
Identifiants
pubmed: 34829769
pii: biomedicines9111540
doi: 10.3390/biomedicines9111540
pmc: PMC8614904
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Instituto de Salud Carlos III, Spanish Ministry of Science and Innovation (COVID-19 research call COV20/00181) - co-financed by the European Development Regional Fund "A way to achieve Europe"
ID : COVID-19 research call COV20/00181
Organisme : Consejeria de Sanidad de la Comunidad de Madrid
ID : CIVICO study 2020/0082
Références
J Infect. 2021 Mar;82(3):378-383
pubmed: 33450302
Clin Transl Gastroenterol. 2021 Apr 9;12(4):e00343
pubmed: 33835096
Clin Microbiol Infect. 2021 Feb;27(2):258-263
pubmed: 33031948
Lancet. 2021 Jan 16;397(10270):220-232
pubmed: 33428867
Med (N Y). 2021 Jun 11;2(6):720-735.e4
pubmed: 33821250
Cytometry A. 2020 Oct;97(10):1044-1051
pubmed: 32830910
J Rehabil Med. 2020 May 25;52(5):jrm00063
pubmed: 32449782
J Infect. 2020 Dec;81(6):e4-e6
pubmed: 32853602
Nat Med. 2020 Jul;26(7):1070-1076
pubmed: 32514174
J Immunol. 2008 Jan 1;180(1):214-21
pubmed: 18097022
Immunity. 2011 Jan 28;34(1):108-21
pubmed: 21215658
J Exp Med. 1998 Jan 5;187(1):129-34
pubmed: 9419219
BMJ. 2021 May 19;373:n1098
pubmed: 34011492
BMC Med. 2021 Sep 27;19(1):249
pubmed: 34565368
Nat Med. 2021 Apr;27(4):626-631
pubmed: 33692530
QJM. 2020 Sep 1;113(9):657-665
pubmed: 32442308
J Clin Invest. 2020 Dec 1;130(12):6290-6300
pubmed: 32784290
JAMA. 2020 Aug 11;324(6):603-605
pubmed: 32644129
Biomedicines. 2021 Aug 05;9(8):
pubmed: 34440170
PLoS Med. 2021 Sep 28;18(9):e1003773
pubmed: 34582441
Front Immunol. 2021 May 07;12:676932
pubmed: 34025675
Nat Med. 2021 Apr;27(4):601-615
pubmed: 33753937
BMJ. 2006 Sep 16;333(7568):575
pubmed: 16950834
J Clin Med. 2021 Aug 24;10(17):
pubmed: 34501230
Clin Exp Immunol. 2021 Aug;205(2):99-105
pubmed: 34082475
J Infect Public Health. 2020 Jul;13(7):926-931
pubmed: 32546439
Sci Transl Med. 2021 Jun 2;13(596):
pubmed: 33941622